Funding for this research was provided by:
Health Research Board ((CSA/2007/11))
Science Foundation Ireland ((08/SRC/B1410))
Irish Research Council
Irish Cancer Society ((CCRC13GAL))
Cancer Clinical Research Trust
Text and Data Mining valid from 2018-10-11
Received: 12 January 2018
Accepted: 24 September 2018
First Online: 11 October 2018
Ethics approval and consent to participate
: LPT109096; NCT00524303 is a phase II study which randomized patients with HER2-positive stage II or III invasive breast cancer to treatment with trastuzumab, lapatinib, or both together with chemotherapy. All data were verified by US Oncology Research and GlaxoSmithKline (US Oncology 05–074, GlaxoSmithKline LPT109096, registration NCT00524303). This study was developed by the Breast Committee of US Oncology Research with GlaxoSmithKline and, in accordance with the precepts of the Helsinki Declaration, was approved by the US Oncology Research central institutional review board, Houston, TX, and clinically performed by US Oncology Research. All patients provided written informed consent.
: All authors have read and approved the final version of the manuscript.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.